Frequency and duration of remission after isolated limb perfusion for melanoma

Archives of Surgery

Volumn 132, Issue 8, 1997, Pages 903-907

  Thompson, John F ^a,b   Hunt, Jeremy A ^a   Shannon, Kerwin F ^a,b   Kam, Peter C ^a,b  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DACTINOMYCIN; SARCOLYSIN;

ARTICLE; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER RECURRENCE; CANCER REGRESSION; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MELANOMA; METASTASIS; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0030838760     PISSN: 00040010     EISSN: None     Source Type: Journal    
DOI: 10.1001/archsurg.1997.01430320105017     Document Type: Article

References (23)

1. Creech OJ, Krementz ET, Ryan RF, Wlnblad JN. Chemotherapy of cancer: regional perfusion utilising an extracorporeal circuit. Ann Surg. 1958;148:616-632.
2. Schraffordt Koops M, Kroon BBR, Lejeune FJ. Isolated regional perfusion in the treatment of local recurrence, satellites and in-transit metastases of extremity melanomas, In: Rumke P, ed. Therapy of Advanced Melanoma: Pigment Cell. Basel, Switzerland: S Karger AG; 1990:67-78.
3. Krementz ET, Ryan RF, Muchmore JH, Carter RD, Sutherland CM, Reed RJ. Hyperthermic regional perfusion for melanoma of the limbs. In: Balch CM, Houghton AN, Milton GW, Sober AJ, Soong S-J, eds. Cutaneous Melanoma. 2nd ed. Philadelphia, Pa: JB Lippincott; 1992:403-426.
4. Colt DG. Hyperthermic isolation limb perfusion for malignant melanoma: a review. Cancer Invest. 1992;10:277-284.
5. Thompson JF, Gianoutsos MP. Isolated limb perfusion for melanoma: effectiveness and toxicity of cisplatin compared with that of melphalan and other drugs. World J Surg. 1992;16:227-233.
6. Thompson JF, Good PD, Kam PCA. Hyperthermic isolated limb perfusion in the treatment of melanoma: technical aspects. Reg Cancer Treat. 1994;7:147-154.
7. Wieberdink J, Benckhuijsen C, Braat RP, Van Slooten EA, Olthuis GAA, Dosimetry in isolated perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions. Eur J Cancer Clin Oncol. 1982;18:905-910.
8. Lejeune FJ, Vaglini M, Schraffordt-Koops H, et al. A randomised trial on prophylactic isolation perfusion for stage 1 high risk (ie, > 1.5-mm thickness) malignant melanoma of the limbs: an interim report. Melanoma Res. 1993;3:95.
9. Kroon BBR. Regional isolated perfusion in melanoma of the limbs: accomplishments, unsolved problems, future. Eur J Surg Oncol. 1988;14:101-110.
10. Hansson JA, Simert G, Vang J. The effect of regional perfusion treatment on recurrent melanoma of the extremities. Acta Chir Scand. 1977;145:33-39.
11. Rosin RD, Westbury G. Isolated limb perfusion for malignant melanoma. Practitioner. 1980;224:1031-1036.
12. Jönsson P-E, Hafström L, Hugander A. Results of regional hyperthermic perfusion for primary and recurrent melanomas of the extremities. Recent Results Cancer Res. 1983;86:277-282.
13. Lejeune FJ, Deloof T, Ewalenko, P et al. Objective regression of unexcised melanoma in-transit metastases after hyperthermic isolation perfusion of the limbs with melphalan. Recent Results Cancer Res. 1983;86:268-276.
14. Storm FK, Morton DL. Value of therapeutic hyperthermic limb perfusion in advanced recurrent melanoma of the lower extremity. Am J Surg. 1985;150:32-35.
15. Di Filippo F, Calabro A, Giannarelli D, et al. Prognostic variables in recurrent limb melanoma treated with hyperthermic antiblastic perfusion. Cancer. 1989;63: 2551-2561.
16. Skene AI, Bulman AS, Williams TR, Meirion-Thomas J, Westbury G. Hyperthermic isolated perfusion with melphalan in the treatment of advanced malignant melanoma of the lower limb. Br J Surg. 1990;77:765-767.
17. Kroon BBR, Klaase JM, van de Merwe SA, van Dongen JA, van der Zee J. Results of a double perfusion schedule using high-dose hyperthermia and melphalan sequentially for recurrent melanoma of the limbs: a pilot study. Reg Cancer Treat. 1992;4:305-308.
18. Lejeune FJ, Lienard D, Leyvraz S, Mirimanoff RO. Regional therapy of melanoma. Eur J Cancer. 1993;4:606-612.
19. Cavaliere R, Cavaliere F, Deraco M, et al. Hyperthermic antiblastic perfusion in the treatment of stage IIIA-IIIAB melanoma patients: comparison of two experiences. Melanoma Res. 1994;4(suppl):5-11.
20. Klaase JM, Kroon BBR, van Geel AN, Eggermont AMM, Franklin HR, Hart AAM. Prognostic factors for tumour response and limb recurrence-free interval in patients with advanced melanoma of the limbs treated with regional isolated perfusion with melphalan. Surgery. 1994;115:39-45.
21. Bryant PJ, Balderson GA, Mead P, Egerton WS. Hyperthermic isolated limb perfusion for malignant melanoma: response and survival. World J Surg. 1995;19: 363-368.
22. Eggermont AMM, Schraffordt Koops H, Lienard D, Lejeune FJ, Oudkerk M. Destruction of tumor-associated vessels by isolated limb perfusion with tumor necrosis factor: angiographic observations in sarcoma patients. Eur J Surg Oncol. 1994;20:403.
23. Klop WMC, Vrouenraets BC, van Geel BN, et al. Repeat isolated limb perfusion with melphalan for recurrent melanoma of the limbs. J Am Coll Surg. 1996;182: 467-472.